Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 12:15 AM ET

Biotechnology

Company Overview of PaxVax, Inc.

Company Overview

PaxVax, Inc. operates as a biotechnology company that develops and commercializes vaccine candidates against various infectious diseases. Its products include PXVX0200, a single-dose oral vaccine against cholera; PXVX0103, an oral adenoviral-based vaccine against avian influenza (H5N1) or bird flu; a single-dose oral vaccine candidate for protection against anthrax; Ad4-env Clade C, a HIV vaccine component that expresses an optimized HIV envelope protein derived from a Clade C HIV strain; Ad4-mGag, a HIV vaccine component that expresses an optimized HIV gag protein; a two-dose whole virus inactivated vaccine candidate that encompasses various strains of dengue fever; and Vivotif, a live typh...

900 Veterans Boulevard

Suite 500

Redwood City, CA 94063

United States

Founded in 2006

Phone:

650-847-1075

Key Executives for PaxVax, Inc.

Chief Executive Officer, President and Director
Executive Chairman
Age: 56
Chief Financial Officer and Executive Vice President
Age: 48
Chief Scientific Officer and Executive Vice President
Chief Legal Officer and Executive Vice President
Compensation as of Fiscal Year 2015.

PaxVax, Inc. Key Developments

Valneva SE and PaxVax, Inc. Enter into Marketing and Distribution Agreement

Valneva SE and PaxVax, Inc. announced that they have entered into a marketing and distribution agreement for their respective travel vaccines, DUKORAL® and Vivotif®. Under the terms of the agreement, Valneva will distribute and promote PaxVax's typhoid vaccine Vivotif® in Canada and the Nordic countries (Sweden, Norway, Denmark and Finland) while PaxVax will distribute and promote Valneva's cholera vaccine DUKORAL® in Italy, Spain and Portugal.

PaxVax, Inc. Announces Executive Changes

PaxVax, Inc. announced that the Board of Directors has appointed Nima Farzan as Chief Executive Officer and President. In this role, he will assume overall responsibility for PaxVax, including management of all R&D, manufacturing and commercial operations globally. Kenneth Kelley, co-founder and former CEO, will continue to serve PaxVax as a Director on the Company’s Board of Directors and as an Advanced Leadership Initiative Fellow at Harvard University focused on related global health issues. Mr. Farzan previously served as President and Chief Operating Officer. He joined PaxVax in September 2011 from Novartis AG. Most recently, he was Vice President of Marketing for Novartis Vaccines USA, where he was responsible for marketing, market access, pricing and key account sales, and also helped launch multiple new vaccines.

PaxVax, Inc. Announces Global Expansion of Commercial Network for its Typhoid Vaccine Vivotif

PaxVax, Inc. announced a series of new commercial partnerships and distribution agreements for its commercial typhoid vaccine Vivotif. These agreements will ensure the global availability of Vivotif across Europe and Australia and complement the company's growing direct sales and marketing capabilities in the United States. Vivotif is currently licensed for sale in 27 countries.Typhoid is one of the most commonly delivered travel vaccines, and these agreements will ensure the availability of Vivotif to people in the European and Australian markets who are travelling to regions of the world where typhoid is endemic. Vivotif is the only oral vaccine indicated for typhoid and look forward to working with new distribution partners to maintain a stable global supply of this effective vaccine.

Similar Private Companies By Industry

Company Name Region
Perlstein Lab PBC United States
Inson Medical Systems, Inc. United States
Synbody Biotechnology, Inc. United States
Clearant, Inc. United States
Invivoscribe Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PaxVax, Inc., please visit www.paxvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.